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A B S T R A C T
Purpose
To determine whether the pattern of lung nodules in children with metastatic hepatoblastoma (HB)
correlates with outcome.
Methods
Thirty-two patients with metastatic HB were enrolled on Children’s Oncology Group Protocol
AHEP0731 and treated with vincristine and irinotecan (VI). Responders to VI received two additional
cycles of VI intermixed with six cycles of cisplatin/ﬂuorouracil/vincristine/doxorubicin (C5VD), and
nonresponders received six cycles of C5VD alone. Patients were imaged after every two cycles and
at the conclusion of therapy. All computed tomography scans and pathology reports were centrally
reviewed, and information was collected regarding lung nodule number, size, laterality, timing of
resolution, and pulmonary surgery.
Results
Among the 29 evaluable patients, only 31% met Response Evaluation Criteria in Solid Tumors
(RECIST) for measurable metastatic disease. The presence of measurable disease by RECIST, the
sum of nodule diameters greater than or equal to the cumulative cohort median size, bilateral
disease, and $ 10 nodules were each associated with an increased risk for an event-free survival
event (P = .48, P = .08, P = .065, P = .03, respectively), with nodule number meeting statistical
signiﬁcance. Ten patients underwent pulmonary resection/metastasectomy at various time points,
the beneﬁt of which could not be determined because of small patient numbers.
Conclusion
Children with metastatic HB have a poor prognosis. Overall tumor burden may be an important
prognostic factor for these patients. Lesions that fail tomeet RECIST size criteria (ie, those, 10mm)
at diagnosis may contain viable tumor, whereas residual lesions at the end of therapymay constitute
eradicated tumor/scar tissue. Patients may beneﬁt from risk stratiﬁcation on the basis of the burden
of lung metastatic disease at diagnosis.
J Clin Oncol 35:3465-3473. © 2017 by American Society of Clinical Oncology
INTRODUCTION
Hepatoblastoma (HB) is the most common pe-
diatric liver malignancy.1,2 Prognosis is based
on surgical resectability of the primary tumor,
presence of metastatic disease, and tumor his-
tology, but only one third of patients have
resectable disease at diagnosis. Neoadjuvant
chemotherapy that is primarily cisplatin and
doxorubicin based has enhanced resectability and
overall survival.3 Approximately 10% to 20%
of patients present with lung metastases, and
overall survival of these children has ranged
between 25% and 50%.4,5 The Societe´ Inter-
nationale d’Oncologie Pediatrique-Epithelial
Liver Tumor Study Group (SIOPEL) 4 trial
recently demonstrated improved survival for
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these high-risk children.4-6 Although surgical resection of the
primary tumor is the basis for curative therapy, the role and beneﬁt
of pulmonary nodule resection remains incompletely evaluated.7,8
The management of pulmonary metastases is particularly relevant
for approximately 20% to 30% of patients in whom orthotopic
liver transplantation (OLT) may be necessary to excise the primary
tumor. Because extrahepatic disease is a contraindication to OLT,
the resolution of pulmonary disease is required to render a patient
a candidate for transplantation.9
Computed tomography (CT) scans are the primary modality
for diagnosing and assessing the response of pulmonary metas-
tases. However, the radiologic deﬁnition of lung involvement is
sometimes challenging. Although the image resolution of CT is on
the order of tenths of centimeters, CT cannot deﬁnitively dis-
tinguish malignant disease from scar tissue, vascular structures,
inﬂammation, or infection and also cannot delineate whether
residual radiographic abnormalities denote persistent viable
disease.10,11 The Response Evaluation Criteria in Solid Tumors
(RECIST) has been used as a guideline to deﬁnemeasurable disease
in patients with solid tumors.12 By original RECIST deﬁnition,
measurable lung lesions must have a longest diameter of$ 10 mm
on CTscan. Therefore, many patients with newly diagnosed disease
may have abnormal lesions on chest CT scan that are considered
nonmeasurable metastatic disease. There have been no prospective
studies that have speciﬁcally characterized lung metastases in
pediatric patients with HB. Given the paucity of data and the
limitations inherent to making a diagnosis on the basis of imaging
alone, there are not currently evidence-based data on the optimal
treatment of patients with pulmonary metastatic disease.
The Children’s Oncology Group (COG) Protocol for Treatment
of Children with All Stages of Hepatoblastoma (AHEP0731) was
designed for all patients with newly diagnosed HB and included
a speciﬁc stratum for patients with metastatic disease.13 A detailed
report on the treatment and outcome of patients with metastatic
disease is published elsewhere. The objective of this paper is to report
the study ﬁndings regarding the surgical management of pulmonary
nodules, to review radiologic considerations for evaluating pul-
monary metastatic disease, and to determine prognostic factors
yielding an evidence-based approach for the treatment of these
patients. We describe the relationship between lung nodule number,
size, laterality (unilateral v bilateral), and total nodule burden, with
chemotherapy response, pulmonary resection, and survival.
METHODS
Patients
AHEP0731 opened in September of 2009. Patients were stratiﬁed
based on COG stage, tumor histology, initial alpha-fetoprotein (AFP) level,
and the presence of metastases as determined by the institutional in-
vestigators. Patients were eligible for the high-risk stratum if they had
either metastatic disease or a low diagnostic AFP level , 100 ng/mL,
regardless of initial extent of disease. Additional eligibility criteria included
age younger than 21 years, newly diagnosed biopsy-proven HB (except in
emergent cases), and normal hematologic, hepatic, renal, and cardiac
function. The study protocol was approved by the National Cancer In-
stitute, the Pediatric Central Institutional Review Board, and the in-
stitutional review boards of participating institutions. Informed consent
was obtained before the treatment of all patients.
Operative reports and central pathologic review of specimens ac-
quired at any time during treatment were required. Central review of
radiographic studies (CT scans, magnetic resonance imaging, and ab-
dominal ultrasounds obtained at any time before tumor resection) was
performed by the study radiologists (A.J.T., M.B.M.) after de-identiﬁcation
at the Imaging and Radiation Oncology Core (IROC-RI, formerly QARC).
When appropriate, response was classiﬁed according to RECIST criteria.14
Pretreatment Extent of Disease (PRETEXT) staging was assessed by central
review.15
Treatment
Patients with high-risk disease received two cycles of vincristine and
irinotecan (VI) as up-front window therapy. Responders to VI were to
receive two additional cycles of VI intermixed with six cycles of cisplatin/
ﬂuorouracil/vincristine/doxorubicin (C5VD), and nonresponders were to
receive six cycles of C5VD alone (Appendix Fig A1, online only).
Patients could have their primary tumor removed whenever feasible,
either by subtotal hepatectomy or via complete hepatectomy with OLT,
optimally after cycle 7 in responders or after cycle 6 in nonresponders, to
allow for postsurgical chemotherapy. Surgical approach to metastatic le-
sions was not mandated by the protocol and was at the discretion of the
treating physicians. If the metastases disappeared with chemotherapy, no
pulmonary surgical intervention was performed. Removal of presumed
metastases was to be considered at any time to render a patient free of
extrahepatic disease and a suitable OLT candidate.
Evaluation of Response
Overall response to therapy was assessed using RECIST criteria as well
as decline of AFP (Appendix, online only). Patients who had complete
resolution of all radiographic disease and a normal AFP at end of therapy
and during follow-up without new disease were deemed to have achieved
a complete remission.
For the purposes of this study, one study radiologist (A.J.T.) reviewed
all chest CT scans. For each patient, the diameter of visualized lung
nodules, of any size, were recorded to a maximum of 10 nodules per
patient. For evaluation of these nodules, RECIST criteria were applied only
when discriminating target lesions. Nodules of all sizes (up to a maximum
of 10 and including those , 10 mm) were used to deﬁne disease burden
and were tracked on serial images to assess response to therapy, reduction
in size, and resolution. Detailed information was collected regarding total
nodule number, individual and cumulative nodule diameters, laterality,
timing of nodule resolution, and size of individual residual lesions at the
end of therapy. Operative and pathology reports were evaluated for all
patients undergoing nodule resection, and the timing of resection, number
of nodules removed, and tumor viability for resected nodules were
recorded.
Statistical Analysis
Event-free survival (EFS) was measured from the time of patient
enrollment until the last follow-up or an analytic event was observed,
whichever occurred ﬁrst (Appendix).16 The effects of pulmonary resection
on the risk of EFS event and death were estimated by time-dependent
covariates methodology. A resection accomplished variable was calculated
for every patient as 0 at the time of enrollment, and this was changed to 1
on the day the pulmonary surgical resection was accomplished and
remained 1 throughout the patient’s subsequent follow-up. The relative
hazard rate for pulmonary resection was estimated by partial likelihood,
and the Wald test was used to obtain the P value for the hypothesis that
pulmonary resection did not affect subsequent risk for EFS event.16
Hypotheses regarding the equality of risk of EFS event or death across
groups deﬁned by other patient characteristics determined at enrollment
were assessed by means of the log-rank statistic.17 P values for all statistical
tests are two sided, and P values # .05 were considered statistically sig-
niﬁcant for this analysis.
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RESULTS
Thirty-two patients, all withmetastatic disease, were enrolled in the
high-risk arm of AHEP0731 between September 2009 and Feb-
ruary 2012. Outcome current to June 30, 2014 was used in this
analysis. Three of the 32 patients enrolled were excluded from this
analysis: one patient was ineligible because of failure to meet organ
function criteria, one patient was not evaluable because of
a technical error in obtaining the initial AFP level, and one patient
did not have conﬁrmation of nodules on central review. The
demographic and treatment data of the evaluation cohort can be
found in Table 1.
Only nine of the 29 patients (31%) had measurable pul-
monary disease at diagnosis by RECIST criteria (nodules $
10 mm), and seven (24%) had all nodules measuring , 5 mm.
Accounting for nodules of any size, the mean and median number
of nodules per patient was six and seven, respectively (range, 1 to
10). The cohort median nodule size, generated from the cumu-
lative sum diameters of all nodules for each individual, was 22 mm
(range, 2 to 209 mm). Twenty patients (69%) had bilateral disease
and nine patients (31%) had unilateral disease (Table 2). There was
no signiﬁcant difference in the number of nodules, laterality, or
total size when stratiﬁed by sex or age.
Response
Table 2 describes the differences in EFS and overall survival
between patients with different clinical features. There was no
statistically signiﬁcant difference in risk for an event between
patients who were initially diagnosed with measurable versus
nonmeasurable metastatic disease (hazard ratio [HR], 1.45; P =
.48), bilateral disease versus unilateral disease (HR, 3.72; P = .065),
or cumulative size , 22 mm versus $ 22 mm (HR, 2.69; P = .08;
Table 2; Fig 1A). However, patients with bilateral disease and
cumulative nodule size greater than the cohort median sum of
diameters had a nominally higher risk of event with HRs of 3.72
and 2.69, respectively (Table 2; Fig 1B). Patients with$ 10 nodules
had signiﬁcantly higher risk of event than those with, 10 nodules
(HR, 3.07; P = .03).
Ten patients had complete radiographic clearance of all
pulmonary metastases. Seven of these resolved with chemo-
therapy; ﬁve of these seven remain event free for a median time of
Table 1. Characteristics of Patients With High-Risk Metastatic
Hepatoblastoma
Characteristic No. (%)
Age 11-159 months (median, 26 months)
, 12 months 1 (3)
1-8 years 27 (93)
. 8 years 1 (3)
Sex
Male 17 (59)
Female 12 (41)
PRETEXT
I
II 9 (31)
III 6 (21)
IV 14 (48)
Surgery
Yes 20 (69)
Resection 16 (55)
Resection during cycles 3-4 2
Resection during cycles 5-7 13
Resection during cycles 8-10 1
Transplant 4 (14)
Transplant during cycles 5-7 1
Transplant during cycles 8-10 3
No 9 (31)
Total 29
Pulmonary surgical procedure 10 (33)
AFP, ng/mL
, 100 0
100-1,000 0
1,000-1,000,000 24 (83)
. 1,000,000 5 (17)
Abbreviations: AFP, alpha-fetoprotein; PRETEXT, Pretreatment Extent of
Disease.
Table 2. Characteristics of Pulmonary Nodules and Outcome
Characteristic No. (%) % 3-year EFS (95% CI) HR (95% CI) P % 3-year OS (95% CI) P
RECIST .48 .80
Measurable 9 (31) 33 (8 to 62) 1.45 (0.51 to 4.11) 67 (28 to 88)
Nonmeasurable 20 (69) 54 (30 to 73) 1* 58 (33 to 76)
Laterality .065‡ .24‡
Bilateral 20 (69) 32 (13 to 53) 3.72 (0.83 to 16.62) 51 (27 to 71)
Unilateral 9 (31) 78 (36 to 94) 1* 78 (36 to 94)
Unilateral disease
Left side only 3 (10) 1 —† 1
Right side only 6 (21) 67 (19 to 90) —† 67 (19 to 90)
No. of nodules .03 .17
, 10 18 (62) 66 (39 to 83) 1* 71 (43 to 87)
$ 10 11 (38) 18 (3 to 44) 3.07 (1.07 to 8.80) 44 (15 to 70)
Nodule cumulative size, mm .08 .39
, 22 14 (48) 71 (41 to 88) 1* 70 (38 to 87)
$ 22 15 (52) 27 (8 to 50) 2.69 (0.85 to 8.53) 51 (24 to 74)
Abbreviations: EFS, event-free survival; HR, hazard ratio; OS, overall survival; RECIST, Response Evaluation Criteria in Solid Tumors.
*Reference category for the hazard ratio.
†HR cannot be estimated for the comparison of left side only versus right side only, because no events were observed in left-side-only patients.
‡Refers to the comparison of patients with bilateral disease with patients with unilateral disease.
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2.9 years (range, 2.4 to 4.2 years) after nodule resolution. The
remaining three patients achieved clearance of pulmonary dis-
ease with both pulmonary resection/metastasectomy and che-
motherapy, and all three remain disease free for a median of 3.6
years (range, 2.6 to 3.7 years) after achieving clearance. Eight of
the 10 patients underwent primary tumor resection while on
protocol therapy. One patient was removed from protocol
therapy and received a liver transplant 2 weeks later. The ﬁnal
patient had resolution of pulmonary disease but local progres-
sion in the liver before resection was performed. There were ﬁve
additional patients with residual radiographic pulmonary
lesions # 3 mm on end-of-therapy scans. Only one of these
patients relapsed in the liver and died; the remaining four are
alive without progression of pulmonary lesions for a me-
dian follow-up of 3.3 years (range, 2.7 to 3.8 years) after last
assessment.
EFS
(n = 3)
EFS
(n = 8)
EFS
(n = 3)
Total patients
 (N = 32)
Excluded
 (n = 3)
Organ function criteria  (n = 1)
 (n = 1)
 (n = 1)
No definite pulmonary nodule
AFP not evaluable
Included
(n = 29)
Measurable
(at least one
lesion > 10 mm; n = 9)
Nonmeasurable
 (n = 20)
A
All lesions < 5 mm
 (n = 7)
5 mm < largest lesion < 10 mm
 (n = 13)
EFS 
(n = 0)
EFS 
(n = 2)
EFS 
(n = 2)
EFS 
(n = 5)
EFS 
(n = 1)
EFS 
(n = 4)
No surgery
 (n = 6)
Surgery
 (n = 3)
No surgery
 (n = 7)
Surgery
 (n = 2)
No surgery
 (n = 6)
Surgery
 (n = 5)
Total patients
 (N = 32)
Bilateral
 (n = 11)
10 nodules
 (n = 11)
Unilateral
 (n = 9)
Bilateral
 (n = 9)
B
< 10 Nodules
 (n = 18)
Excluded
 (n = 3)
Organ function criteria  (n = 1)
 (n = 1)
 (n = 1)
No definite pulmonary nodule
AFP not evaluable
Included
(n = 29)
Fig 1. (A) Nodule size and event-free sur-
vival (EFS). (B) Nodule characteristics, pul-
monary surgeries, and EFS.
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Outcome
Three-year EFS was 49% (95% CI, 30% to 65%), and overall
survival was 62% (95% CI, 42% to 77%; Fig 2). Fifteen patients are
alive without progression for a median follow-up of 3.2 years
(range, 0.5 to 4.6 years; Table 3). Thirteen patients had recurrent
disease. Two patients died without relapse while receiving therapy:
one patient had a cardiac arrest after a GI procedure and another
died of post-resection complications. Nine patients did not have
resection of the primary tumor while receiving protocol therapy.
Five of these patients had progressive disease while receiving
therapy: three were pulmonary, one combined pulmonary and
liver, and one liver alone. Three patients were removed from
protocol because of physician choice and still had pulmonary
nodules at the time they were removed from protocol therapy, and
one additional patient completed therapy but did not have surgery
because of persistence of lung nodules.
Pulmonary Resection/Metastasectomy
Ten of 29 patients (34%) had resection of pulmonary met-
astatic disease (Table 4). Of these, two surgeries were performed as
diagnostic biopsies and eight occurred later in therapy. There were
no reported complications related to pulmonary nodule resection.
The median number of metastases removed in these patients was
three (range, 1 to 12). Pulmonary resection/metastasectomy was
not related signiﬁcantly to subsequent risk for EFS event or death
(P = .11, P = .67, respectively; Table 2). Five of the 11 patients with
10 documented nodules had a pulmonary surgery performed
sometime during the course of treatment, and all recurred. Two of
these patients remain alive, with follow-up of 45 and 46 months,
with a normal AFP, having received no additional chemotherapy.
Of the eight patients who had pulmonary resection after initiation
of chemotherapy (ie, excluding those who underwent up-front
diagnostic biopsy of the pulmonary lesions), pathology demon-
strated the presence of viable tumor in ﬁve patients; ﬁve relapsed
and three were alive with follow-up of 43, 45, and 46 months
(Table 4). The number of patients is too small to determine the
importance of viable tumor and the relationship to timing of
resection.
DISCUSSION
To our knowledge, this is the largest prospective report detailing
characteristics and outcome of childrenwith pulmonary metastatic
HB and the ﬁrst to report that the burden of pulmonary metastatic
disease is an adverse prognostic factor. When taking into account
nodules of all sizes, a signiﬁcant increase in risk for an event was
associated only with number of nodules (, 10 v$ 10). There were
nonsigniﬁcant increases in risk associated with laterality (bilateral v
unilateral) and total burden of metastatic pulmonary disease
(, 22 mm v $ 22 mm). Although these ﬁndings may seem in-
tuitive, they are critically important in assessing current treatment
paradigms and considering new algorithms and clinical trial de-
signs, because traditional RECIST criteria may not be the optimal
method for evaluating disease response and predicting outcome in
HB. Only a third of patients had measurable lesions by RECIST
criteria, whereas seven patients had all pulmonary nodules, 5 mm.
The potential beneﬁt of pulmonary resection/metastasectomy could
not be determined in our series because of small numbers, the
variable timing of surgery, and the number of nodules removed.
Therefore, in this disease where primary tumor resection is critical
for survival, the effect of surgical resection of both limited and
extensive pulmonary metastatic disease remains unknown and an
important area to be further studied in future trials.
In our cohort, 3-year overall survival of 62% (median follow-
up, 38 months) was better than previous COG studies but not as
good as the 3-year 79% overall survival (median follow-up,
53 months) reported for metastatic disease in the recent
SIOPEL 4 trial.3,6 In this trial, 19 of 39 patients with metastatic
disease (49%) achieved a complete chemotherapy response of lung
nodules, and 27 (69%) had resection of all lung lesions, with no
detail provided on the number of lesions resected in each patient.
The role of surgical resection/metastasectomy for HB may be most
beneﬁcial in two distinct populations of patients: those whose
presenting lung disease fails to clear with chemotherapy, especially
to facilitate OLT, and those who achieve a complete response and
then develop a pulmonary relapse. Surgical lung resection was
evaluated by Meyers et al8 in both of these cohorts of children
treated on the COG protocol INT-0098. Of these 38 children, nine
underwent pulmonary resection at varying points in therapy, and
eight of these nine patients (89%) were long-term survivors. In that
same study, there were 20 patients with pulmonary relapse after
complete response. Thirteen of these 20 patients underwent
pulmonary resection, but only four of these 13 (31%) were long-
term survivors.8
There are several retrospective reports in the surgical literature
exploring the role of pulmonary resection in other pediatric solid
tumors. Many of these studies intuitively conclude that nodule
resection is most beneﬁcial across disease types for lesions that
persist after chemotherapy and less so for patients with progressive
disease.18-20 Some studies conclude that number of metastases, as
shown here, and unilaterality are the most signiﬁcant prognostic
factors for survival.21,22 All studies demonstrate that pulmonary
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Fig 2. Event-free survival (EFS) and overall survival (OS) of patients with met-
astatic hepatoblastoma.
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resection/metastasectomy is safe and can be performed without
signiﬁcant morbidity.20,21,23,24
Radiographic scans are limited in their ability to determine
whether a nodule contains viable tumor. Three of eight patients
who had nodule resection performed during protocol therapy had
no viable tumor. In addition, four surviving patients had residual
radiographic abnormalities at the end of therapy, with biopsy not
performed. These ﬁndings suggest that treatment decisions cannot
depend solely on the presence of radiographic lesions but must take
into account total nodule burden, change in size over time, lesion
stability, and serum AFP levels (Table 4), with the consideration
that residual lesions of stable size may represent eradicated tumor
or scar. Biopsy at end of therapy should be entertained for patients
in whom serum AFP levels fail to normalize and/or nodules fail to
change or diminish appreciably in size.
There is a comprehensive body of literature detailing the
limitations inherent to imaging studies in their ability to detect
small lesions, particularly lung metastases. For diseases in which
thoracotomy and manual lung palpation are routine (ie, pediatric
osteosarcoma), it has been demonstrated that the number of
intraoperative lesions often far exceeds the number identiﬁed by
CT scan.18,21 Although this may change over time with the evo-
lution of CT technology, at present, CT is relied on heavily to
determine the quantity and size of lung lesions at diagnosis, to
assess disease response to therapy, to guide surgical intervention,
and to assure retained remission after therapy.25,26 Although the
deﬁnitive detection of metastases is clearly limited by technology, it
remains to be seen whether deviating from RECIST criteria to
consider lung lesions of smaller size (ie, # 5 mm) may serve as
a better reﬂection of disease burden, predict the impact of lung
metastases on prognosis, and more appropriately guide therapy.
Ultimately, patients with bilateral lung disease and a signiﬁ-
cant lung tumor burden may be candidates for novel therapies or
treatment strategies. The use of maintenance therapy with iri-
notecan has been described to have success in small numbers of
patients.27 Radiotherapy for metastatic disease has been anec-
dotally reported but never formally studied.28 A more aggressive
up-front surgical approach to resect nodules at diagnosis or in-
tensiﬁcation of therapy for patients unable to clear lung nodules
with conventional chemotherapy agents could also be considered.
Treatment decisions optimally should be made with some as-
sessment of pathologic response of remaining nodules in con-
junction with AFP decline, because persistent radiographic
abnormalities may not indicate residual tumor.
Although the recent Children’s Hepatic Tumors International
Collaboration (CHIC) publication conﬁrmed metastatic disease
to be a poor prognostic factor, it did not incorporate more
details regarding pulmonary metastases.29 The upcoming
Pediatric Hepatic Malignancy International Therapeutic Trial
(PHITT) will allow an opportunity to determine the relevance of
these factors prospectively and on a much larger scale. Future trials
may help conﬁrm the novel preliminary ﬁndings demonstrated
here and should use a consistent approach toward lung metastases,
with potential risk stratiﬁcation on the basis of total nodule
burden.
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Appendix
Treatment
Each cycle of vincristine and irinotecan (VI) consisted of intravenous (IV) irinotecan (50 mg/m2/d or 1.67 mg/kg for pa-
tients, 10 kg, IVover 90 minutes, on days 1 to 5) and vincristine (1.5 mg/m2/dose or 0.05 mg/kg for patients, 10 kg, IV push, on
days 2, 9, and 16). Patients were then evaluated for response, and those demonstrating at least a partial response to VIwere to receive
six cycles of cisplatin, ﬂuorouracil, vincristine, and doxorubicin (C5VD) and two additional cycles of VI (inserted in between each
two-cycle block of C5VD) for a total of 10 cycles. Those patients who did not respond to VI were to continue with six cycles of
C5VD without additional VI. Each course of C5VD included cisplatin (100 mg/m2 or 3.33 mg/kg for patients , 10 kg, IV over 6
hours, on day 1), ﬂuorouracil (600 mg/m2 or 20 mg/kg for patients, 10 kg, IV push, on day 2), vincristine as described above, and
doxorubicin (30mg/m2/d or 1 mg/kg/d for patients, 10 kg, IVover 15minutes, on days 1 and 2). All patients received dexrazoxane
(300 mg/m2 or 10 mg/kg for patients , 10 kg) IV immediately before doxorubicin during the last two cycles of C5VD. All cycles
lasted 21 days.
Evaluation of Response
Baseline physical examinations, organ function, alpha-fetoprotein (AFP) levels, and imaging studies, including a computed
tomography scan of the chest, were performed before therapy. Additional imaging studies were performed after two cycles of VI and
then after every two cycles of C5VD. Assessment of response for study treatment was determined by the treating site. Evaluation of
response for the purposes of assessing the efﬁcacy of VI therapy after the ﬁrst two cycles was based on central imaging review and
change in serum AFP level from the time of study enrollment to the completion of two cycles of VI. Overall response to therapy was
assessed using Response Evaluation Criteria in Solid Tumors (RECIST) criteria as well as the decline of AFP.
Measurable disease was considered using RECIST to be the presence of at least one target lesion, deﬁned as a lesion having
a longest diameter of at least 10 mm on spiral computed tomography scan. A complete response was considered to be the
disappearance of all target lesions and a normal AFP level (by institutional standards). A partial response was considered as either at
least a 30% decrease in the sum of diameters of target lesions compared with baseline or a decline in serum AFP level of $ 90%
(1 log10) after two VI cycles, provided the patient did not experience progressive disease during the ﬁrst two cycles of therapy.
Statistical Analysis
Analytic events for this cohort were progression of disease or occurrence of disease at new sites; treatment failure, deﬁned as the
presence of disease after planned chemotherapy; death from any cause before disease progression; or diagnosis of a second
malignancy. A patient who did not experience an event before the date of analysis for the trial was considered censored at last patient
contact. Overall survival was deﬁned from the time of enrollment until death from any cause or last follow-up, whichever came ﬁrst.
A patient who did not die before the date of analysis for the trial was considered censored at last patient contact.
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END
END
Window
assessment
NR
R
Evaluations
Vincristine/irinotecan C5VD
Fig A1. Treatment schema. C5VD, cisplatin/ﬂuorouracil/vincristine/doxorubicin; NR, nonresponders; R, responders.
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